{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T20:59:06Z","timestamp":1767992346873,"version":"3.49.0"},"reference-count":14,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T00:00:00Z","timestamp":1763337600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>A 55-year-old man presented to the emergency department (ED) with diffuse abdominal pain, vomiting, and anuria following a night of heavy alcohol intake. The patient\u2019s medical history included hypertension. Two weeks prior to presentation, he was prescribed etoricoxib for back pain. On presentation, he was found to have severe acute kidney injury, and dialysis was initiated. Renal biopsy showed acute interstitial nephritis with numerous eosinophilic infiltrates. Despite stopping etoricoxib and initiating high-dose steroids, kidney function did not improve. The administration of benralizumab\u2014an anti-CD125 antibody\u2014resulted in rapid and complete recovery of kidney function. This case report highlights the potential role of benralizumab in the treatment of drug-induced interstitial nephritis with eosinophiluria.<\/jats:p>","DOI":"10.3389\/fimmu.2025.1720992","type":"journal-article","created":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T05:16:22Z","timestamp":1763356582000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Case Report: A potential novel treatment for drug-induced acute interstitial nephritis: Benralizumab"],"prefix":"10.3389","volume":"16","author":[{"given":"Alexander","family":"Saadia","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ron","family":"Wald","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Assaf","family":"Potruch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Galina","family":"Pizov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen","family":"Meir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kobi","family":"Gorin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Inon","family":"Sarig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eyal Ben","family":"Dori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Limor","family":"Rubin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yaarit","family":"Ribak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Odded","family":"Shamriz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuval","family":"Tal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aviv","family":"Talmon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,11,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1093\/ndt\/gfs143","article-title":"Spanish Registry of Glomerulonephritis. Increased prevalence of acute tubulointerstitial nephritis","volume":"28","author":"Goicoechea","year":"2013","journal-title":"Nephrol Dial Transplant"},{"key":"B2","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1038\/ki.2010.89","article-title":"Acute interstitial nephritis","volume":"77","author":"Praga","year":"2010","journal-title":"Kidney Int"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ki.5002776","article-title":"Early steroid treatment improves recovery of renal function in patients with drug-induced acute interstitial nephritis","volume":"73","author":"Gonza\u0301lez","year":"2008","journal-title":"Kidney Int"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2014.04.027","article-title":"Biopsy-proven acute interstitial nephritis 1993\u20132011: A case series","volume":"64","author":"Muriithi","year":"2014","journal-title":"Am J Kidney Dis"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.01390118","article-title":"Duration of corticosteroid treatment and recovery of kidney function in acute interstitial nephritis","volume":"13","author":"Fernandez-Juarez","year":"2018","journal-title":"Clin J Am Soc Nephrol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/nrneph.2010.71","article-title":"Drug-induced acute interstitial nephritis","volume":"6","author":"Perazella","year":"2010","journal-title":"Nat Rev Nephrol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)31322-8","article-title":"Benralizumab, an anti-interleukin-5 receptor \u03b1 monoclonal antibody, as an add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomized, double-blind, placebo-controlled phase 3 trial","volume":"388","author":"FitzGerald","year":"2016","journal-title":"Lancet"},{"key":"B8","unstructured":"FASENRA benralizumab (FASENRA)"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2313318","article-title":"Eosinophil depletion with benralizumab for eosinophilic esophagitis","volume":"390","author":"Rothenberg","year":"2024","journal-title":"New Engl J Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.alit.2020.10.001","article-title":"Efficacy of off-label IL-5-modulating treatments in rare eosinophil-mediated diseases","volume":"70","author":"Shamriz","year":"2021","journal-title":"Allergol Int"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2010.04.004","article-title":"MEDI-563, a humanized anti-IL-5 receptor alpha mAb with enhanced antibody-dependent cell-mediated cytotoxicity function","volume":"125","author":"Kolbeck","year":"2010","journal-title":"J Allergy Clin Immunol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2014.294","article-title":"Clinical characteristics, causes and outcomes of acute interstitial nephritis in the elderly","volume":"87","author":"Muriithi","year":"2015","journal-title":"Kidney Int"},{"key":"B13","doi-asserted-by":"publisher","first-page":"e127456","DOI":"10.1172\/jci.insight.127456","article-title":"Urine TNF-\u03b1 and IL-9 for clinical diagnosis of acute interstitial nephritis","volume":"4","author":"Moledina","year":"2019","journal-title":"JCI Insight"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S392155","article-title":"Safety, tolerability, and pharmacokinetics of benralizumab: A phase 1, randomized, single-blind study of healthy chinese participants","volume":"17","author":"Cheung","year":"2023","journal-title":"Drug Des Devel Ther"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1720992\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T05:16:24Z","timestamp":1763356584000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1720992\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,17]]},"references-count":14,"alternative-id":["10.3389\/fimmu.2025.1720992"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1720992","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,17]]},"article-number":"1720992"}}